The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M

Not for distribution in or into the United States of America, Canada,
Japan or Australia.

Active Biotech has five projects in clinical phase, of which
laquinimod and RhuDex(TM) are managed and financed by partners. The
clinical projects that are managed and financed on a proprietary
basis are TASQ, 57-57 and ANYARA. The potential value of the projects
increases in pace with their advancement in clinical development,
thereby continuously raising shareholder value. In 2009/2010, new
information and clinical data will be published relating to all three
of these projects.

To strengthen the company's financial position and further drive the
development of the company's clinical portfolio, the Board of Active
Biotech has resolved to propose that the Annual General Meeting
resolve to make a new share issue of approximately SEK 256 M with
preferential rights for the shareholders.

It is proposed that the issue shall entitle existing shareholders
with preferential rights to subscribe for one new share for each four
shares held at an issue price of SEK 20 per share.

Read the complete press release below.